{"doi":"10.1002/adhm.202101387","title":"Engineered Cell‐Derived Vesicles Displaying Targeting Peptide and Functionalized with Nanocarriers for Therapeutic microRNA Delivery to Triple‐Negative Breast Cancer in Mice","abstract":"Polymeric nanocarriers (PNCs) can be used to deliver therapeutic microRNAs (miRNAs) to solid cancers. However, the ability of these nanocarriers to specifically target tumors remains a challenge. Alternatively, extracellular vesicles (EVs) derived from tumor cells show homotypic affinity to parent cells, but loading sufficient amounts of miRNAs into EVs is difficult. Here, it is investigated whether uPAR-targeted delivery of nanococktails containing PNCs loaded with therapeutic antimiRNAs, and coated with uPA engineered extracellular vesicles (uPA-eEVs) can elicit synergistic antitumor responses. The uPA-eEVs coating on PNCs increases natural tumor targeting affinities, thereby enhancing the antitumor activity of antimiRNA nanococktails. The systemic administration of uPA-eEV-PNCs nanococktail shows a robust tumor tropism, which significantly enhances the combinational antitumor effects of antimiRNA-21 and antimiRNA-10b, and leads to significant tumor regression and extension of progression free survival for syngeneic 4T1 tumor-bearing mice. In addition, the uPA-eEV-PNCs-antimiRNAs nanococktail plus low dose doxorubicin results in a synergistic antitumor effect as evidenced by inhibition of tumor growth, reduction of lung metastases, and extension of survival of 4T1 tumor-bearing mice. The targeted combinational nanococktail strategy could be readily translated to the clinical setting by using autologous cancer cells that have flexibility for ex vivo expansion and genetic engineering.","journal":"Advanced Healthcare Materials","year":2021,"id":165556,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":36,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9431,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":292420,"name":"Uday Kumar Sukumar","orcid":"0000-0002-0354-2353","position":1,"is_corresponding":false},{"id":260481,"name":"Fernando Jose Garcia-Marques","orcid":"0000-0002-2105-2905","position":2,"is_corresponding":false},{"id":236252,"name":"Yitian Zeng","orcid":"0000-0002-6949-8033","position":3,"is_corresponding":false},{"id":260488,"name":"Frezghi Habte","orcid":"0000-0002-9488-3427","position":4,"is_corresponding":false},{"id":292424,"name":"Jason R. McCarthy","orcid":"0000-0002-5302-2030","position":5,"is_corresponding":false},{"id":240820,"name":"Sharon J. Pitteri","orcid":"0000-0002-3119-873X","position":6,"is_corresponding":false},{"id":292425,"name":"Tarik F. Massoud","orcid":"0000-0002-9694-1408","position":7,"is_corresponding":false},{"id":292426,"name":"Ramasamy Paulmurugan","orcid":"0000-0001-7155-4738","position":8,"is_corresponding":false},{"id":293733,"name":"Rajendran JC Bose","orcid":null,"position":0,"is_corresponding":true}],"reference_count":45,"raw_metadata":null,"created_at":"2026-07-18T23:45:40.838485Z","pmid":"34879180","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}